Poupak Fallahi1
Silvia Martina Ferrari2
Giusy Elia2
Francesca Ragusa2
Sabrina Rosaria Paparo2
Armando Patrizio2
Stefania Camastra2
Mario Miccoli2
Gabriella Cavallini1
Salvatore Benvenga3,4,5
Alessandro Antonelli6*- 1Department of Translational Research of New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy
- 2Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy
- 3Section of Endocrinology, Department of Clinical and Experimental Medicine, University of Messina, Messina, Italy
- 4Master Program on Childhood, Adolescent and Women’s Endocrine Health, University of Messina, Messina, Italy
- 5Interdepartmental Program of Molecular & Clinical Endocrinology, and Women’s Endocrine Health, University Hospital, A.O.U. Policlinico Gaetano Martino, Messina, Italy
- 6Department of Surgical, Medical and Molecular Pathology and Critical Care, University of Pisa, Pisa, Italy
Graves’ disease (GD) is an organ-specific autoimmune disorder of the thyroid, which is characterized by circulating TSH-receptor (TSH-R) stimulating antibodies (TSAb), leading to hyperthyroidism. Graves’ ophthalmopathy (GO) is one of GD extra-thyroidal manifestations associated with the presence of TSAb, and insulin-like growth factor-1 receptor (IGF-1R) autoantibodies, that interact with orbital fibroblasts. Cytokines are elevated in autoimmune (i.e., IL-18, IL-6) and non-autoimmune hyperthyroidism (i.e., TNF-α, IL-8, IL-6), and this could be associated with the chronic effects of thyroid hormone increase. A prevalent Th1-immune response (not related to the hyperthyroidism per se, but to the autoimmune process) is reported in the immune-pathogenesis of GD and GO; Th1-chemokines (CXCL9, CXCL10, CXCL11) and the (C-X-C)R3 receptor are crucial in this process. In patients with active GO, corticosteroids, or intravenous immunoglobulins, decrease inflammation and orbital congestion, and are considered first-line therapies. The more deepened understanding of GO pathophysiology has led to different immune-modulant treatments. Cytokines, TSH-R, and IGF-1R (on the surface of B and T lymphocytes, and fibroblasts), and chemokines implicated in the autoimmune process, are possible targets of novel therapies. Drugs that target cytokines (etanercept, tocilizumab, infliximab, adalimumab) have been tested in GO, with encouraging results. The chimeric monoclonal antibody directed against CD20, RTX, reduces B lymphocytes, cytokines and the released autoantibodies. A multicenter, randomized, placebo-controlled, double-masked trial has investigated the human monoclonal blocking antibody directed against IGF-1R, teprotumumab, reporting its effectiveness in GO. In conclusion, large, controlled and randomized studies are needed to evaluate new possible targeted therapies for GO.
Introduction
Graves’ disease (GD) is an organ-specific autoimmune disorder and it is the most frequent cause of hyperthyroidism in West Countries (1–3). It affects overall women, typically in their third to fifth decade, with an overall prevalence of 0.5% (4).
Clinical manifestations are linked to hyperthyroidism and to the autoimmune process. GD-associated signs and symptoms can vary markedly, influencing the overall well-being (5, 6).
GD is one of the principal autoimmune thyroid disorders (AITD), which are associated with the failure of immune tolerance against thyroid antigens [thyroid-stimulating hormone (TSH) receptor (TSH-R), thyroid peroxidase (TPO), and thyroglobulin (Tg)] (7, 8). At the basis of GD, an autoimmune multifactorial mechanism is present, which acts through environmental and endogenous factors in genetically predisposed individuals (9). GD is characterized by thyrotoxicosis, circulating anti-thyroid antibodies (ATA) and autoreactive lymphocytes into the thyroid (10).
The autoimmune reaction in GD induces the release of anti-TSH-R autoantibodies (TRAb) by B-cell clones, which infiltrate the thyroid, and are implicated in GD pathogenesis and its extrathyroidal manifestations, such as pretibial myxedema (PTM)/Graves’ dermopathy and Graves’ ophthalmopathy (GO). TRAb can be distinguished in: neutral antibodies; thyroid blocking antibodies (TBAb); thyroid stimulating antibodies (TSAb) (11). TSAb have similar downstream effects such as the binding of TSH to TSH-R, leading to thyrocytes proliferation, and secretion of thyroid hormones (TH; T4 and T3) (11, 12).
GD is associated to another autoimmune disease in ~20% of patients (13). A study evaluated prospectively the prevalence of other autoimmune diseases in GD patients (including some GO patients) vs. healthy controls, or patients with autoimmune thyroiditis (AT), or with multinodular goiter (MNG) (gender- and age-matched, and with a similar iodine intake). In 1.5% of GD, three associated autoimmune disorders were present. Patients with GO had a higher prevalence (18.9%) of another autoimmune disorder than GD patients without GO (15.6%) (13).
Graves’ Ophthalmopathy
According to the European Group on Graves’ Orbitopathy (EUGOGO), GO has a prevalence of 10/10,000 persons and 16/10,000 persons in Europe and Japan, respectively (14, 15).
Approximately 30% to 50% of patients with GD develop GO. Tearing, proptosis, periorbital edema, and diplopia are the characteristic signs of Graves’ orbitopathy (16).
Orbital fibroblasts (OF) are the target of a variety of autoimmune responses, that taking together induce proliferation, adipogenesis and overproduction of the extracellular matrix, that includes glycosaminoglycans [GAG; i.e., hyaluronan (HA) and chondroitin sulfate] (4).
GD is a phasic disorder characterized during the active phase by hyperthyroidism, which can go in remission both after therapy or sometimes spontaneously. The recurrence of hyperthyroidism can occur after weeks or decades of euthyroidism, overall owing to physical or psychological stressful events (2). Also, GO is characterized by the presence of moderate-severe inflammatory signs during the active phase that can remit after therapy or spontaneously. Mild GO disappears spontaneously in the majority of cases (17). The most frequent factors associated with the recurrence of GO are stressful life events (2), and smoking (18). Smoking cessation can improve the outcome for GO (3, 4). Components of cigarette smoke might induce adipogenesis and synthesis of GAG, through reactive oxygen species (ROS) production, and whether vaping could have some negative effects on GO is still to be clarified, as nicotine induces the release of pro-inflammatory cytokines (4, 19). As well as in GD, an autoimmune response is at the basis of GO. T cells, and autoantibodies recognizing a common autoantigen both for the thyroid and retro-ocular tissues (such as TSH-R, that is expressed also on fibroblasts and orbital preadipocytes), have a crucial role in this process (20). Moreover, another autoantigen, the insulin-like growth factor-1 (IGF-1) receptor (IGF-1R), has been suggested to be linked to GO (21). Autoantibodies against IGF-1R take part in the activation of GO OF, and its elevated expression has been shown in the thyroid and in orbital tissues in GD patients (20).
Therapies for GO
An anti-inflammatory treatment is suggested in the active phase of GO. A euthyroid state is mandatory for successful treatment and radioiodine therapy should be avoided in active progressive GO (15).
In patients with active GO, corticosteroids (CS), or high dose intravenous (iv) immunoglobulins, decrease inflammation and orbital congestion (22). A prospective, randomized trial compared the efficacy and safety of two protocols of iv 4.5 g methylprednisolone (MP) in 80 patients, randomized to receive iv MP weekly or daily. The weekly protocol of iv MP therapy was more efficient and safer than the daily protocol for patients with active moderate-to-severe GO (23).
According to randomized controlled trials, a meta-analysis reported in patients treated with iv glucocorticoids that a reduction of 1.14 mm of proptosis and of 33% of diplopia is present, while non-randomized studies reported a reduction of 1.58 mm of proptosis and of 25% of diplopia (24). After 6 weeks, in case of worsening of the disease the therapy should be supplemented or substituted with second-line treatments (15), such as orbital radiotherapy (25, 26). Orbital decompression should be done in severe GO (27).
Patients with severe GO can have a reduced quality of life (QoL) during standard therapies and, for this reason, novel treatments, targeting directly the pathogenic disease mechanisms in GO, are necessary to improve the clinical outcome in these patients.
At present, the more deepened understanding of GO pathophysiology has led to alternative immune-modulant therapies that target various antigens (28, 29).
The aim of new treatments for thyroidal and extrathyroidal GD is firstly to target the principal autoantigens of the disease and/or molecules that have a key role in the immunological response. Future treatments of GD, and GO, will involve monoclonal antibodies (mAb) or small molecules (15).
A mechanism for targeting the pathophysiology of GD, and GO, is to “mask” the TSH-R from the action of thyroid-stimulating immunoglobulin (TSI), through the TSH-R antagonist, K1-70 (15, 30, 31). An open-label clinical trial (clinical trial number NCT02904330) is currently in progress to assess its safety and tolerability in patients with hyperthyroidism in GD (32).
A small TSH-R antagonist (clinical trial number NCGC00229600) has been shown to reduce the synthesis of HA in retro-ocular fibroblasts/adipocytes in GO, with good results (33).
Furthermore, an encouraging treatment in GO patients is teprotumumab (RV 001, R1507), a recombinant, human mAb of the immunoglobulin G1 subclass. It binds to the cysteine-rich domain of human IGF-1R with high affinity, preventing the binding with endogenous ligands (IGF-1 and IGF-2), and leading to the internalization of the receptor, in this way stopping the IGF-1R signaling cascade (34–37).
As written above, active GO is linked to the autoimmune activation of OF. This causes the production of cytokines that promote T-cell infiltration into orbital tissues, triggering a local inflammatory process, and resulting in growth and differentiation of fibroblasts, and remodeling of orbital tissues. Teprotumumab blocks these pathophysiological responses (36).
Teprotumumab decreased in vitro TSH-R and IGF-1R, the TSH- and IGF-1–dependent phosphorylated Akt levels in fibrocytes, such as the TSH induction of IL-6 and IL-8 mRNA and protein (38).
A randomized, double-masked study was performed, to evaluate the effectiveness and safety of this drug in 88 patients with active, moderate-to-severe GO, administered with placebo, or the drug (eight infusions) (39). The primary end point was the response in the study eye. This response was defined as a reduction of two points or more in the Clinical Activity Score (CAS) and a reduction of 2 mm or more in proptosis at week 24. About 69% of patients taking teprotumumab, in comparison to 20% of those receiving placebo, had a response at week 24 (P<0.001). At week 6, 43% of patients administered with teprotumumab and 4% with placebo had a response (P<0.001). The reported findings in active GO demonstrated that teprotumumab, compared to placebo, is more effective in decreasing proptosis and CAS (39).
Another randomized, double-masked, phase III multicenter trial was done in patients with active GO in a 1:1 ratio to receive iv teprotumumab (10 mg/kg of body weight for the 1st infusion and 20 mg/kg for the following ones) or placebo once every 3 weeks for 21 weeks, for a total of 24 weeks (40). At week 24, the response in proptosis was higher in patients treated with teprotumumab than with placebo (83% vs. 10%, P<0.001). Secondary findings were significantly better with teprotumumab than with placebo (P ≤ 0.001). The data demonstrated that teprotumumab led to better outcomes (than placebo) with regard to proptosis, CAS, diplopia, and QoL, with uncommon severe adverse events (40).
Teprotumumab attained the approval by the U.S. Food and Drug Administration (FDA) as first drug for thyroid eye disease in March 2020 (41, 42).
Another emerging therapy is rituximab (RTX), a chimeric mAb against CD20. It was approved by FDA in Wegener’s granulomatosis, chronic lymphocytic leukemia, non-Hodgkin’s lymphoma, and rheumatoid arthritis (RA), and it is an off-label drug in different autoimmune diseases (43). Since RTX reduces B lymphocytes, the cytokine burden and the produced autoantibodies, its use has been proposed also in GO.
Two randomized trials showed contrasting results regarding the use of RTX. In the 1st prospective, randomized, placebo-controlled trial, RTX was not effective in 25 GO patients, showing no improvement of CAS (44). In the other randomized, double-blinded study, 32 patients took iv MP or RTX, and CAS decreased in both cases, overall with RTX. After 24 weeks, all patients receiving RTX ameliorated with respect to 69% after ivMP, showing RTX was more effective than ivMP in GO patients (45).
More recently, a meta-analysis and systematic review was done in 293 GO patients, treated with RTX, or glucocorticoids, or saline, to evaluate the effectiveness of RTX. It was shown a significant decrease of CAS (vs. controls) in patients receiving RTX at 24 weeks, and a not significant one of proptosis (46).
In another study (47), 219 GO patients received pulse MP, and then oral steroids and/or orbital radiotherapy. At last, 15 (6.8%) were administered with 100 mg RTX (100–400 mg as cumulative dose) for the presence of active GO. A low dose of RTX had an anti-inflammatory effect in patients with active GO resistant to standard treatments (47). Another paper agreed with those results in 12 patients with active GO treated with a 100 mg RTX infusion; it reported that a low dose of RTX is effective in these patients, thus leading to a reduced administration of systemic steroid (48).
Furthermore, 14 patients with active and moderate-to-severe GO, of whom 11 CS-refractory, were administered with ivRTX (1000 mg twice with a 2-week interval), reporting that RTX was well-tolerated (49). A modest amelioration of CAS, and disease inactivation in half of the patients, were reported. At week 12, CAS ameliorated in 14.3% of patients and inactivation of GO in 28.6%. At week 24, total eye score and proptosis improved in 28.6% and 33% of patients, respectively.
Cytokines and Drugs Targeting Cytokines, in GD and GO
Cytokines in GD and GO
Cytokines [including interleukins (IL), tumor necrosis factors (TNFs), interferons (IFNs), lymphokines, and chemokines] are small proteins, important in normal physiology, and in host responses to infection, trauma, reproduction, inflammation, sepsis, and tumors (10).
They are produced by different cell types, including immune cells (B and T lymphocytes, mast cells, macrophages), fibroblasts, endothelial cells, and different stromal cells, and act through receptors (Table 1).
Table 1 Main cytokines implicated in Graves’ ophthalmopathy, the cells producing them and their biological effects.
Chemokines are “chemotactic cytokines”, or signaling proteins, which can induce directed chemotaxis in the responsive cells. Chemokines exert their biological effects through the interaction with G-protein-linked transmembrane receptors, which are present on their target cells (10). The chemokine receptor (C-X-C)R3 binds Th1-chemokines [IFN-γ-inducible protein 10 (IP-10)/chemokine ligand 10 (C-X-C motif) (CXCL)10, IFN-inducible T-cell α chemoattractant (I-TAC)/CXCL11 and monokine induced by IFN-γ (MIG)/CXCL9] (60). Th1 lymphocytes are attracted in inflamed tissues by Th1 chemokines, that are released there (61), and increase cytokines production, leading to Th1 chemokines secretion by different cells, establishing an amplification feedback loop (62). Raised serum and tissue Th1 chemokines levels have been demonstrated in specific autoimmune disorders [autoimmune thyroiditis (AT) (63–65), GD and GO (52), etc.], or systemic rheumatological diseases [systemic sclerosis, psoriasis or psoriatic arthritis (66, 67), etc.], hepatitis C virus infection related autoimmune disorders (68), and cancer (69, 70).
Certain serum cytokines are elevated in non-autoimmune (IL-8, TNF-α, and IL-6) (71) and autoimmune (IL-18 and IL-6) (72) hyperthyroidism, and this could be due to the chronic effects of TH excess, and not to the coexisting autoimmune condition at the basis of GD (73).
A Th1 immune response is more prevalent in the active phase of GD, and GO; CXCR3 and Th1 chemokines (CXCL9, CXCL10, CXCL11) are crucial in this process, while a switch in immune prevalence from a Th1 to a Th2 response is present in the inactive or later phases (1, 74).
Systemic hyperthyroidism and T cell infiltration into orbital tissue leads to ROS production, which can aggravate GO severity by increasing T cell proliferation, adipogenesis, and GAG production in OF (75). Recently, the role of the protein tyrosine phosphatase 1B (PTP1B), encoded by the PTPN1 gene, has been characterized in GO (76). PTP1B is known to be involved in immune cell signaling by regulating cytokines via dephosphorylation of janus kinase (JAK)2, signal transducer and activator of transcription (STAT)5, and tyrosine kinase (TYK)2. After 24 h of transfection with PTPN1 siRNA, the fibroblasts were exposed to IL-1β, cigarette smoke extract (CSE), H2O2, and transforming growth factor (TGF)-β stimulations. PTPN1 silencing ameliorated ROS generation in both CSE- and H2O2-stimulated cells. The changes in the phosphorylation level of multiple transcription factors after PTP1B inhibition in GO OF indicate a more complex network of signaling pathways. PTP1B inhibition suppressed IL-1β–induced Akt, and JNK phosphorylation, but p38 MAPK phosphorylation was reduced only in GO OF. As the p38 and JNK pathways, and the MAPK pathway, can mediate the transcription and translation of inflammatory cytokines, this study demonstrated that PTP1B mediates inflammatory reactions in GO OF (76).
Inflammation and cytokine production, adipogenesis, and HA synthesis are the prevailing processes implicated in the pathogenesis of GO (20). In the initial phases of GO, the prevalent Th1 immune response facilitates cell-mediated immunity, leading to the production of IFN-γ, TNF-α, IL-1β, and IL-2, that increase fibroblast proliferation and GAG synthesis. IFN-γ induces the secretion of Th1 chemokines by fibroblasts, and the migration of lymphocytes is promoted (54). IL-1β further stimulates the synthesis of GAG (77) and the production of CCL2, CCL5, IL-6, IL-16, IL-8, and neutrophils, by OF (78). Then, inflammation leads to Th2 lymphocytes activation, that release cytokines (i.e., IL-13, IL-10, IL-5, and IL-4), and to humoral reactions and the production of IgG (79). Tissue remodeling and fibrosis characterize the late phase of GO (20).
OF express also the costimulatory protein CD40, and its binding to the ligand CD154, on T cells, induces the production of different inflammatory mediators by OF [CCL2, IL-1α, prostaglandin E2 (PGE2), IL-6, and IL-8] (80–82).
GD OF include cell subsets with specific cellular markers, such as the CD34+ CXCR4 + Collagen 1+ phenotype (CD34+ OF), while CD34− OF do not display them. On the other hand, OF obtained from normal subjects are CD34− OF (55). The axon guidance glycoprotein Slit2 is produced by CD34− OF, and it inhibits fibrocyte differentiation and modulates their characteristic gene expression profile. Slit2 upregulates IL-12 expression and it attenuates that of IL-23, which are both involved in GD and GO (83). CD34+ fibrocytes obtained from peripheral blood mononuclear cells (PBMCs) produce low basal levels of HA, very few of which were affected by bovine thyrotropin (bTSH). On the other hand, GD OF synthesize higher levels of HA, both basally and after the treatment with bTSH. The treatment of confluent cultures with rhSlit2 increases HA production in fibrocytes, while the knock-down of Slit2 expression attenuates its synthesis in GD OF. Considering HA synthase isoenzymes (HAS1–3), low HAS1 levels are present in fibrocytes, while HAS2 is the most strongly expressed in GD OF. Slit2 alters the pattern of HAS and uridine diphosphate (UDP) glucose dehydrogenase (UDPGD) expression and cytokine production, both in GD OF and fibrocytes. The exogenous rhSlit2 causes a transition from HAS1 dominating expression to that of HAS2 in fibrocytes, decreasing also the expression of TNF-α and IL-6. These data suggest that HA synthesis in GD OF depends on the CD34− OF cell subset, while TNF-α and IL-6 expression is present in CD34+ OF. For these reasons GD OF, comprising both CD34+ OF and CD34− OF, can generate inflammatory factors (84, 85).
The activation of OF by TRAb suggests the link between GD and GO. The increased OF activity contributes to the fibrosis of the orbital tissues, causing inflammatory cell infiltration, and edema. Consequently, the optic nerve can be compressed leading to optic neuropathy. The inflammation and swelling of the eye muscles are involved in the final exophthalmos (20).
Furthermore, TSH-R–expressing T cells, which could be activated by TRAb, could stimulate adipogenesis of OF in GO through a peroxisome proliferator-activated receptor-γ (PPAR-γ) ligand produced via upregulated cyclooxygenase (4). CD34+ fibrocytes, such as OF, migrate from the circulation into sites of inflammation and injury and express two of the major GO thyroid autoantigens, TSH-R and thyroglobulin (4). Both CD4+ and CD8+ T cells, and B cells, are present in the majority of GO orbits, and the level of infiltration correlates with disease activity (86). Macrophages are found in the orbits in early disease, whereas monocytes and mast cells have been associated with secretion of platelet-derived growth factor, that stimulates OF proliferation and HA production, in particular the platelet-derived growth factor-BB isoform in OF from both patients with/without GO (4). Mast cells also produce prostaglandins, which are able to enhance adipogenesis (87). In light of the above, there are multiple overlapping factors in the development of GO, and cytokines are strongly involved in its pathogenesis.
Drugs Targeting Cytokines, in GD and GO
Drugs that target cytokines (etanercept, tocilizumab, infliximab, adalimumab) have been tested in GO, with encouraging results.
OF have an increased expression of TSH-R, and a strong up-regulation of TNF-α and IL-6, in the pathogenesis of GO (88).
The association between elevated circulating TNF-α levels and the severity of GO has led to the use of mAb against TNF-α, such as infliximab and etanercept (89, 90). The effectiveness of infliximab in severe steroid and surgical-resistant GO has recently been demonstrated in three cases, with complete resolution after three doses of 5 mg/kg body weight given 1 month apart (91, 92). Moreover, a positive effect of infliximab administration on active GO in a 58-year-old woman with GD has been described, in whom a single dose of this drug resulted in a reduction of inflammation and improvement of visual function, determined by magnetic resonance imaging and CAS and NO SPECS scales, with no noticeable short-term side effects (93).
Etanercept is usually used to treat RA (29). The use of etanercept has been evaluated as potential treatment in 10 patients with active GO, showing remission in 6/10 (89). Moreover, a paper reported the case of a woman, initially diagnosed with primary hypothyroidism (in substitutive treatment with levothyroxine) and subsequently with RA, who had insufficient therapeutic effectiveness with a conventional medication. After 3 years, she showed symptoms and signs of GO. Then, the patient received etanercept for RA, and after 4 months, the ocular symptoms ameliorated and exophthalmos decreased, showing that RA and GO can share similar pathogenic characteristics (88).
Furthermore adalimumab, that has been approved by FDA for psoriatic arthritis, ankylosing spondylitis, inflammatory bowel disease, RA, showed a significant amelioration in the inflammatory composite score in a retrospective review (94).
In patients with active GO, IL-6 and its soluble receptor are activated. Tocilizumab is a humanized mAb recognizing the IL-6R, which attained the approval in Castleman’s disease, systemic juvenile idiopathic arthritis, and RA. A prospective non-randomized study has been conducted in 18 GO patients (refractory to CS) treated with tocilizumab (95). An amelioration of proptosis was reported in 13 patients, extraocular motility in 15, and 7/13 solved the problem of diplopia, with no relapse of GO at the end of the follow-up. These data suggested that tocilizumab might be effective in GO patients resistant to steroids (95). Furthermore, a reduction in extraocular muscle thickness and chemosis was reported after therapy with tocilizumab in patients with GO, by using an optical coherence tomography. Four women and one man with a median age of 52 years (range, 38–73 years) were enrolled. Median GO activity duration was 17 months (12–18). After tocilizumab, median muscle thicknesses and chemosis reduced. Median CAS decreased from 5 (4–8) to 1 (0–3) (96). More recently, a paper reported three GO patients refractory to CS or with advanced diplopia, receiving tocilizumab (8 mg/kg; monthly iv), and it showed a significant amelioration in eye symptoms (97).
Conclusion
GO is one of the extrathyroidal manifestations of GD. In patients with GO, OF can differentiate into myofibroblasts or adipocytes, able to interact with mononuclear cells, that produce chemoattractants and cytokines, in this way reiterating orbital inflammation.
Certain cytokines are elevated in autoimmune (i.e. IL-18 and IL-6) and non-autoimmune hyperthyroidism (i.e. TNF-α, IL-8, and IL-6), supporting the idea that this may be associated with the chronic effects of TH increase, and not with the GD inflammatory, autoimmune condition.
A prevalent Th1 immune response is reported in the immune-pathogenesis of GD and GO; Th1 chemokines (CXCL9, CXCL10, CXCL11), and the CXCR3, are crucial in this process
Patients with active, mild GO usually benefit from local therapies and selenium, whereas patients with moderate-to-severe disease generally need the addition of iv glucocorticoids. In case of an inadequate response to glucocorticoid therapy, different second-line therapies have been evaluated, such as orbital radiotherapy (with additional glucocorticoids), RTX, mycophenolate mofetil, cyclosporine, and methotrexate. Novel biologic agents, in particular teprotumumab and tocilizumab, have shown strong reductions in disease activity and severity. If these data are confirmed in the future, the treatment paradigm could be changed. Moreover, new immunotherapies are now evaluated for GD, that may have treatment implications also for GO (30).
At present, the more deepened understanding of GO pathophysiology has led to different immune-modulant treatments. Cytokines, TSH-R and IGF-1R (on the surface of B and T lymphocytes, and fibroblasts), and chemokines implicated in the autoimmune process, are possible targets of novel therapies.
The remodeled tissues in GO are dominated by adipogenesis, the increase of HA into the orbit, and the local synthesis of proinflammatory cytokines (including TNF-α and IL-6). There is a high complexity in the interactions among the cells of the heterogeneous population of GD OF in the GO orbit. Slit2 seems to play an important role in the determination of the pattern of HAS and UDPGD expression and IL-6, TNF-α, and HA production in these fibroblasts, and it could be considered as an interesting therapeutic target in GO (84, 85).
In the pathogenesis of GO, OF have an increased expression of TSH-R, and a strong up-regulation of TNF-α and IL-6. Drugs that target cytokines have been tested in GO, with encouraging results. The association between elevated circulating TNF-α levels and the severity of GO has led to the use of mAb against TNF-α, such as infliximab, adalimumab, and etanercept. Also tocilizumab (anti-IL6-R) have reached significant findings in GO.
In conclusion, large, controlled and randomized studies are needed to evaluate new possible targeted therapies for GO.
Author Contributions
PF, SMF, SB, and AA conceived the paper. All authors contributed to the article and approved the submitted version.
Conflict of Interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
References
1. Antonelli A, Ferrari SM, Corrado A, Di Domenicantonio A, Fallahi P. Autoimmune thyroid disorders. Autoimmun Rev (2015) 14:174–80. doi: 10.1016/j.autrev.2014.10.016
2. Smith TJ, Hegedüs L. Graves’ disease. N Engl J Med (2016) 375:1552–65. doi: 10.1056/NEJMra1510030
3. Antonelli A, Ferrari SM, Ragusa F, Elia G, Paparo SR, Ruffilli I, et al. Graves’ disease: Epidemiology, genetic and environmental risk factors and viruses. Best Pract Res Clin Endocrinol Metab (2020) 34:101387. doi: 10.1016/j.beem.2020.101387
4. Taylor PN, Zhang L, Lee RWJ, Muller I, Ezra DG, Dayan CM, et al. New insights into the pathogenesis and nonsurgical management of Graves orbitopathy. Nat Rev Endocrinol (2020) 16:104–16. doi: 10.1038/s41574-019-0305-4
5. Vaidya B, Pearce SH. Diagnosis and management of thyrotoxicosis. BMJ (2014) 349:g5128. doi: 10.1136/bmj.g5128
6. Antonelli A, Fallahi P, Elia G, Ragusa F, Paparo SR, Ruffilli I, et al. Graves’ disease: Clinical manifestations, immune pathogenesis (cytokines and chemokines) and therapy. Best Pract Res Clin Endocrinol Metab (2020) 34:101388. doi: 10.1016/j.beem.2020.101388
7. Romagnani S. The Th1/Th2 paradigm and allergic disorders. Allergy (1998) 53:12–5. doi: 10.1111/j.1398-9995.1998.tb04951.x
8. McLachlan SM, Rapoport B. Breaking tolerance to thyroid antigens: changing concepts in thyroid autoimmunity. Endocr Rev (2014) 35:59–105. doi: 10.1210/er.2013-1055
9. Wémeau JL, Klein M, Sadoul JL, Briet C, Vélayoudom-Céphise FL. Graves’ disease: introduction, epidemiology, endogenous and environmental pathogenic factors. Ann Endocrinol (2018) 79:599–607. doi: 10.1016/j.ando.2018.09.002
10. Ferrari SM, Ruffilli I, Elia G, Ragusa F, Paparo SR, Patrizio A, et al. Chemokines in hyperthyroidism. J Clin Transl Endocrinol (2019) 16:100196. doi: 10.1016/j.jcte.2019.100196
11. Kotwal A, Stan M. Thyrotropin receptor antibodies-an overview. Ophthalmic Plast Reconstr Surg (2018) 34(4S Suppl 1):S20–7. doi: 10.1097/IOP.0000000000001052
12. Kahaly GJ, Diana T, Kanitz M, Frommer L, Olivo PD. Prospective Trial of Functional Thyrotropin Receptor Antibodies in Graves Disease. J Clin Endocrinol Metab (2020) 105:e1006–14. doi: 10.1210/clinem/dgz292
13. Ferrari SM, Fallahi P, Ruffilli I, Elia G, Ragusa F, Benvenga S, et al. The association of other autoimmune diseases in patients with Graves’ disease (with or without ophthalmopathy): review of the literature and report of a large series. Autoimmun Rev (2019) 18:287–92. doi: 10.1016/j.autrev.2018.10.001
14. Perros P, Hegedüs L, Bartalena L, Marcocci C, Kahaly GJ, Baldeschi L, et al. Graves’ orbitopathy as a rare disease in Europe: a European Group on Graves’ Orbitopathy (EUGOGO) position statement. Orphanet J Rare Dis (2017) 12:72. doi: 10.1186/s13023-017-0625-1
15. Davies TF, Andersen S, Latif R, Nagayama Y, Barbesino G, Brito M, et al. Graves’ disease. Nat Rev Dis Primers (2020) 6:52. doi: 10.1038/s41572-020-0184-y
16. Davies TF, Burch HB. Clinical features and diagnosis of Graves’ orbitopathy (ophthalmopathy) (2019). Available at: https://www.uptodate.com/contents/pathogenesis-of-graves-disease/ (Accessed 14 Jan 2021).
17. Bartalena L, Baldeschi L, Boboridis K, Eckstein A, Kahaly GJ, Marcocci C, et al. The 2016 European Thyroid Association/European Group on Graves’ Orbitopathy Guidelines for the Management of Graves’ Orbitopathy. Eur Thyroid J (2016) 5(1):9–26. doi: 10.1159/000443828
18. Perricone C, Versini M, Ben-Ami D, Gertel S, Watad A, Segel MJ, et al. Smoke and autoimmunity: the fire behind the disease. Autoimmun Rev (2016) 15:354–74. doi: 10.1016/j.autrev.2016.01.001
19. Cawood TJ, Moriarty P, O’Farrelly C, O’Shea D. Smoking and thyroid- associated ophthalmopathy: a novel explanation of the biological link. J Clin Endocrinol Metab (2007) 92:59–64. doi: 10.1210/jc.2006-1824
20. Łacheta D, Miśkiewicz P, Głuszko A, Nowicka G, Struga M, Kantor I, et al. Immunological Aspects of Graves’ Ophthalmopathy. Biomed Res Int (2019) 2019:7453260. doi: 10.1155/2019/7453260
21. Place RF, Krieger CC, Neumann S, Gershengorn MC. Inhibiting thyrotropin/insulin-like growth factor 1 receptor crosstalk to treat Graves’ ophthalmopathy: studies in orbital fibro blasts in vitro. Br J Pharmacol (2017) 174:328–40. doi: 10.1111/bph.13693
22. Antonelli A, Saracino A, Alberti B, Canapicchi R, Cartei F, Lepri A, et al. High-dose intravenous immunoglobulin treatment in Graves’ ophthalmopathy. Acta Endocrinol (Copenh) (1992) 126(1):13–23. doi: 10.1530/acta.0.1260013
23. Zhu W, Ye L, Shen L, Jiao Q, Huang F, Han R, et al. A prospective, randomized trial of intravenous glucocorticoids therapy with different protocols for patients with graves’ ophthalmopathy. J Clin Endocrinol Metab (2014) 99(6):1999–2007. doi: 10.1210/jc.2013-3919
24. Zang S, Ponto KA, Kahaly GJ. J. Clinical review: intravenous glucocorticoids for Graves’ orbitopathy: efficacy and morbidity. J Clin Endocrinol Metab (2011) 96:320–32. doi: 10.1210/jc.2010-1962
25. Bartalena L, Veronesi G, Krassas GE, Wiersinga WM, Marcocci C, Marinò M, et al. Does early response to intravenous glucocorticoids predict the final outcome in patients with moderate-to-severe and active Graves’ orbitopathy? J Endocrinol Invest (2017) 40:547–53. doi: 10.1007/s40618-017-0608-z
26. Tanda ML, Bartalena L. Efficacy and safety of orbital radiotherapy for Graves’ orbitopathy. J Clin Endocrinol Metab (2012) 97:3857–65. doi: 10.1210/jc.2012-2758
27. Currò N, Covelli D, Vannucchi G, Campi I, Pirola G, Simonetta S, et al. Therapeutic outcomes of high-dose intravenous steroids in the treatment of dysthyroid optic neuropathy. Thyroid (2014) 24:897–905. doi: 10.1089/thy.2013.0445
28. Fallahi P, Ferrari SM, Elia G, Nasini F, Colaci M, Giuggioli D, et al. Novel Therapies for Thyroid Autoimmune Diseases. Expert Rev Clin Pharmacol (2016) 9:853–61. doi: 10.1586/17512433.2016.1157468
29. Ferrari SM, Fallahi P, Elia G, Ragusa F, Camastra S, Paparo SR, et al. Novel therapies for thyroid autoimmune diseases: An update. Best Pract Res Clin Endocrinol Metab (2020) 34:101366. doi: 10.1016/j.beem.2019.101366
30. Genere N, Stan MN. Current and Emerging Treatment Strategies for Graves’ Orbitopathy. Drugs (2019) 79:109–24. doi: 10.1007/s40265-018-1045-9
31. Sanders P, Young S, Sanders J, Kabelis K, Baker S, Sullivan A, et al. Crystal structure of the TSH receptor (TSHR) bound to a blocking-type TSHR autoantibody. J Mol Endocrinol (2011) 46:81–99. doi: 10.1530/JME-10-0127
32. Available at: https://clinicaltrials.gov/ct2/show/NCT02904330 (Accessed 14 Jan 2021).
33. Turcu AF, Kumar S, Neumann S, Coenen M, Iyer S, Chiriboga P, et al. A small molecule antagonist inhibits thyrotropin receptor antibody-induced orbital fibroblast functions involved in the pathogenesis of Graves ophthalmopathy. J Clin Endocrinol Metabol (2013) 98:2153–9. doi: 10.1210/jc.2013-1149
34. Smith TJ, Janssen JA. Building the case for insulin-like growth factor receptor-I involvement in thyroid-associated ophthalmopathy. Front Endocrinol (Lausanne) (2016) 7:167. doi: 10.3389/fendo.2016.00167
35. Smith TJ, Janssen J. Insulin-like growth factor-I receptor and thyroid-associated ophthalmopathy. Endocr Rev (2019) 40:236–67. doi: 10.1210/er.2018-00066
36. Kahaly GJ. Immunotherapies for thyroid eye disease. Curr Opin Endocrinol Diabetes Obes (2019) 26:250–5. doi: 10.1097/MED.0000000000000493
37. Mohyi M, Smith TJ. IGF1 receptor and thyroid-associated ophthalmopathy. J Mol Endocrinol (2018) 61:T29–43. doi: 10.1530/JME-17-0276
38. Chen H, Mester T, Raychaudhuri N, Kauh CY, Gupta S, Smith TJ, et al. Teprotumumab, an IGF-1R blocking monoclonal antibody inhibits TSH and IGF-1 action in fibrocytes. J Clin Endocrinol Metab (2014) 99:E1635–40. doi: 10.1210/jc.2014-1580
39. Smith TJ, Kahaly GJ, Ezra DG, Fleming JC, Dailey RA, Tang RA, et al. Teprotumumab for Thyroid-Associated Ophthalmopathy. N Engl J Med (2017) 376:1748–61. doi: 10.1056/NEJMoa1614949
40. Douglas RS, Kahaly GJ, Patel A, Sile S, Thompson EHZ, Perdok R, et al. Teprotumumab for the Treatment of Active Thyroid Eye Disease. N Engl J Med (2020) 382:341–52. doi: 10.1056/NEJMoa1910434
41. Smith TJ. Thyroid-associated ophthalmopathy: Emergence of teprotumumab as a promising medical therapy. Best Pract Res Clin Endocrinol Metab (2020) 34:101383. doi: 10.1016/j.beem.2020.101383
42. Horizon therapeutics plc announces the FDA has granted priority review of the teprotumumab biologics license application (BLA) for the treatment of active thyroid eye disease (TED) (2019). Available at: https://ir.horizontherapeutics.com/news-releases/news-release-details/horizon-therapeutics-plc-announces-fda-has-granted-priority (Accessed 14 Jan 2021).
43. Giuggioli D, Lumetti F, Colaci M, Fallahi P, Antonelli A, Ferri C. Rituximab in the treatment of patients with systemic sclerosis. Our experience and review of the literature. Autoimmun Rev (2015) 14:1072–8. doi: 10.1016/j.autrev.2015.07.008
44. Stan MN, Garrity JA, Carranza Leon BG, Prabin T, Bradley EA, Bahn RS. Randomized controlled trial of rituximab in patients with Graves’ orbitopathy. J Clin Endocrinol Metab (2015) 100:432–41. doi: 10.1210/jc.2014-2572
45. Salvi M, Vannucchi G, Currò N, Campi I, Covelli D, Dazzi D, et al. Efficacy of B-cell targeted therapy with rituximab in patients with active moderate to severe Graves’ orbitopathy: a randomized controlled study. J Clin Endocrinol Metab (2015) 100:422–31. doi: 10.1210/jc.2014-3014
46. Shen WC, Lee CH, Loh EW, Hsieh AT, Chen L, Tam KW. Efficacy and safety of rituximab for the treatment of graves’ orbitopathy: a meta-analysis of randomized controlled trials. Pharmacotherapy (2018) 38:503–10. doi: 10.1002/phar.2111
47. Du Pasquier-Fediaevsky L, Andrei S, Berche M, Leenhardt L, Héron E, Rivière S. Low-dose rituximab for active moderate to severe graves’ orbitopathy resistant to conventional treatment. Ocul Immunol Inflamm (2019) 27:844–50. doi: 10.1080/09273948.2018.1453078
48. Insull EA, Sipkova Z, David J, Turner HE, Norris JH. Early low-dose rituximab for active thyroid eye disease: an effective and well-tolerated treatment. Clin Endocrinol (2019) 91:179–86. doi: 10.1111/cen.13970
49. Eid L, Coste-Verdier V, Longueville E, Ribeiro E, Nicolescu-Catargi B, Korobelnik JF. The effects of Rituximab on Graves’orbitopathy: a retrospective study of 14 patients. Eur J Ophthalmol (2019) 30:1008–13. doi: 10.1177/1120672119845224
50. Heufelder AE, Bahn RS. Detection and localization of cytokine immunoreactivity in retro-ocular connective tissue in Graves’ ophthalmopathy. Eur J Clin Invest (1993) 23:10–7. doi: 10.1111/j.1365-2362.1993.tb00712.x
51. Ludgate M, Baker G. Unlocking the immunological mechanisms of orbital inflammation in thyroid eye disease. Clin Exp Immunol (2002) 127:193–8. doi: 10.1046/j.1365-2249.2002.01792.x
52. Antonelli A, Ferrari SM, Fallahi P, Piaggi S, Paolicchi A, Franceschini SS, et al. Cytokines (interferon-γ- and tumor necrosis factor-α)-induced nuclear factor-κB activation and chemokine (C-X-C motif) ligand 10 release in Graves disease and ophthalmopathy are modulated by pioglitazone. Metabolism (2011) 60:277–83. doi: 10.1016/j.metabol.2010.02.002
53. Antonelli A, Rotondi M, Ferrari SM, Fallahi P, Romagnani P, Franceschini SS, et al. Interferon-gamma-inducible alpha-chemokine CXCL10 involvement in Graves’ ophthalmopathy: modulation by peroxisome proliferator-activated receptor-gamma agonists. J Clin Endocrinol Metab (2006) 91:614–20. doi: 10.1210/jc.2005-1689
54. Antonelli A, Ferrari SM, Fallahi P, Frascerra S, Santini E, Franceschini SS, et al. Monokine induced by interferon gamma (IFNgamma) (CXCL9) and IFNgamma inducible T-cell alpha-chemoattractant (CXCL11) involvement in Graves’ disease and ophthalmopathy: modulation by peroxisome proliferator-activated receptor-gamma agonists. J Clin Endocrinol Metab (2009) 94:1803–9. doi: 10.1210/jc.2008-2450
55. Smith TJ. Potential roles of CD34+ fibrocytes masquerading as orbital fibroblasts in thyroid-associated ophthalmopathy. J Clin Endocrinol Metab (2019) 104:581–94. doi: 10.1210/jc.2018-01493
56. Fang S, Huang Y, Zhong S, Zhang Y, Liu X, Wang Y, et al. IL-17A Promotes RANTES Expression, But Not IL-16, in Orbital Fibroblasts Via CD40-CD40L Combination in Thyroid-Associated Ophthalmopathy. Invest Ophthalmol Vis Sci (2016) 57:6123–33. doi: 10.1167/iovs.16-20199
57. Ferrari SM, Ragusa F, Paparo SR, Nasini F, Nardi M, Franceschini SS, et al. Differential modulation of CXCL8 versus CXCL10, by cytokines, PPAR-gamma, or PPAR-alpha agonists, in primary cells from Graves’ disease and ophthalmopathy. Autoimmun Rev (2019) 18:673–8. doi: 10.1016/j.autrev.2019.05.004
58. Chen MH, Chen MH, Liao SL, Chang TC, Chuang LM. Role of macrophage infiltration in the orbital fat of patients with Graves’ ophthalmopathy. Clin Endocrinol (Oxf) (2008) 69:332–7. doi: 10.1111/j.1365-2265.2008.03219.x
59. Antonelli A, Ferrari SM, Corrado A, Franceschini SS, Gelmini S, Ferrannini E, et al. Extra-ocular muscle cells from patients with Graves’ ophthalmopathy secrete α (CXCL10) and β (CCL2) chemokines under the influence of cytokines that are modulated by PPARγ. Autoimmun Rev (2014) 13:1160–6. doi: 10.1016/j.autrev.2014.08.025
60. Lasagni L, Francalanci M, Annunziato F, Lazzeri E, Giannini S, Cosmi L, et al. An alternatively spliced variant of CXCR3 mediates the inhibition of endothelial cell growth induced by IP-10, Mig, and I-TAC, and acts as functional receptor for platelet factor 4. J Exp Med (2003) 197:1537–49. doi: 10.1084/jem.20021897
61. Tokunaga R, Zhang W, Naseem M, Puccini A, Berger MD, Soni S, et al. CXCL9, CXCL10, CXCL11/CXCR3 axis for immune activation – a target for novel cancer therapy. Cancer Treat Rev (2018) 63:40–7. doi: 10.1016/j.ctrv.2017.11.007
62. Antonelli A, Ferrari SM, Giuggioli D, Ferrannini E, Ferri C, Fallahi P. Chemokine (C-X-C motif) ligand (CXCL)10 in autoimmune diseases. Autoimmun Rev (2014) 13:272–80. doi: 10.1016/j.autrev.2013.10.010
63. Antonelli A, Ferrari SM, Frascerra S, Di Domenicantonio A, Nicolini A, Ferrari P, et al. Increase of circulating CXCL9 and CXCL11 associated with euthyroid or subclinically hypothyroid autoimmune thyroiditis. J Clin Endocrinol Metab (2011) 96:1859–63. doi: 10.1210/jc.2010-2905
64. Antonelli A, Ferrari SM, Fallahi P, Ghiri E, Crescioli C, Romagnani P, et al. Interferon-alpha, -beta and -gamma induce CXCL9 and CXCL10 secretion by human thyrocytes: modulation by peroxisome proliferator-activated receptor-gamma agonists. Cytokine (2010) 50:260–7. doi: 10.1016/j.cyto.2010.01.009
65. Fallahi P, Ferrari SM, Ruffilli I, Elia G, Biricotti M, Vita R, et al. The association of other autoimmune diseases in patients with autoimmune thyroiditis: review of the literature and report of a large series of patients. Autoimmun Rev (2016) 15:1125–8. doi: 10.1016/j.autrev.2016.09.009
66. Antonelli A, Ferri C, Fallahi P, Colaci M, Giuggioli D, Ferrari SM, et al. Th1 and Th2 chemokine serum levels in systemic sclerosis in the presence or absence of autoimmune thyroiditis. J Rheumatol (2008) 35:1809–11.
67. Antonelli A, Fallahi P, Delle Sedie A, Ferrari SM, Maccheroni M, Bombardieri S, et al. High values of alpha (CXCL10) and beta (CCL2) circulating chemokines in patients with psoriatic arthritis, in presence or absence of autoimmune thyroiditis. Autoimmunity (2008) 41:537–42. doi: 10.1080/08916930802170401
68. Ferrari SM, Fallahi P, Mancusi C, Colaci M, Manfredi A, Ferri C, et al. HCV-related autoimmune disorders in HCV chronic infection. Clin Ter (2013) 164:e305–12. doi: 10.7417/CT.2013.1594
69. Antonelli A, Ferrari SM, Fallahi P, Piaggi S, Di Domenicantonio A, Galleri D, et al. Variable modulation by cytokines and thiazolidinediones of the prototype Th1 chemokine CXCL10 in anaplastic thyroid cancer. Cytokine (2012) 59:218–22. doi: 10.1016/j.cyto.2012.04.042
70. Ferrari SM, Fallahi P, Galdiero MR, Ruffilli I, Elia G, Ragusa F, et al. Immune and Inflammatory Cells in Thyroid Cancer Microenvironment. Int J Mol Sci (2019) 20:4413. doi: 10.3390/ijms20184413
71. Siddiqi A, Monson JP, Wood DF, Besser GM, Burrin JM. Serum cytokines in thyrotoxicosis. J Clin Endocrinol Metab (1999) 84:435–9. doi: 10.1210/jcem.84.2.5436
72. Salvi M, Pedrazzoni M, Girasole G, Giuliani N, Minelli R, Wall JR, et al. Serum concentrations of proinflammatory cytokines in Graves’ disease: effect of treatment, thyroid function, ophthalmopathy and cigarette smoking. Eur J Endocrinol (2000) 143:197–202. doi: 10.1530/eje.0.1430197
73. Antonelli A, Fallahi P, Rotondi M, Ferrari SM, Romagnani P, Grosso M, et al. Increased serum CXCL10 in Graves’ disease or autoimmune thyroiditis is not associated with hyper- or hypothyroidism per se, but is specifically sustained by the autoimmune, inflammatory process. Eur J Endocrinol (2006) 154:651–8. doi: 10.1530/eje.1.02137
74. Fallahi P, Ferrari SM, Ragusa F, Ruffilli I, Elia G, Paparo SR, et al. Th1 Chemokines in Autoimmune Endocrine Disorders. J Clin Endocrinol Metab (2020) 105:dgz289. doi: 10.1210/clinem/dgz289
75. Venditti P, Di Meo S. Thyroid hormone-induced oxidative stress. Cell Mol Life Sci (2006) 63:414–34. doi: 10.1007/s00018-005-5457-9
76. Byeon HJ, Kim JY, Ko J, Lee EJ, Don K, Yoon JS. Protein tyrosine phosphatase 1B as a therapeutic target for Graves’ orbitopathy in an in vitro model. PloS One (2020) 15:e0237015. doi: 10.1371/journal.pone.0237015
77. Han R, Smith TJ. T helper type 1 and type 2 cytokines exert divergent influence on the induction of prostaglandin E2 and hyaluronan synthesis by interleukin-1β in orbital fibroblasts: implications for the pathogenesis of thyroidassociated ophthalmopathy. Endocrinology (2006) 147:13–9. doi: 10.1210/en.2005-1018
78. Chen B, Tsui S, Smith TJ. IL-1 beta induces IL-6 expression in human orbital fibroblasts: identification of an anatomic-site specific phenotypic attribute relevant to thyroid- associated ophthalmopathy. J Immunol (2005) 175:1310–9. doi: 10.4049/jimmunol.175.2.1310
79. Mikoś H, Mikoś M, Obara-Moszyńska M, Niedziela M. The role of the immune system and cytokines involved in the pathogenesis of autoimmune thyroid disease (AITD). Endokrynol Pol (2014) 65:150–5. doi: 10.5603/EP.2014.0021
80. Hwang CJ, Afifiyan N, Sand D, Naik V, Said J, Pollock SJ, et al. Orbital fibroblasts from patients with thyroid-associated ophthalmopathy overexpress CD40: CD154 hyper induces IL-6, IL-8, and MCP-1. Invest Ophthalmol Vis Sci (2009) 50:2262–8. doi: 10.1167/iovs.08-2328
81. Kuehn HS, Jung MY, Beaven MA, Metcalfe DD, Gilfillan AM. Prostaglandin E2 activates and utilizes mTORC2 as a central signaling locus for the regulation of mast cell chemotaxis and mediator release. J Biol Chem (2011) 286:391–402. doi: 10.1074/jbc.M110.164772
82. Zhao LQ, Wei RL, Cheng JW, Cai JP, Li Y. The expression of intercellular adhesion molecule-1 induced by CD40-CD40L ligand signaling in orbital fibroblasts in patients with Graves’ ophthalmopathy, Invest. Opthalmol Vis Sci (2010) 51:4652–60. doi: 10.1167/iovs.09-3789
83. Fernando R, Atkins SJ, Smith TJ. Slit2 may underlie divergent induction by thyrotropin of IL-23 and IL-12 in human fibrocytes. J Immunol (2020) 204:1724–35. doi: 10.4049/jimmunol.1900434
84. Fernando R, Smith TJ. Slit2 regulates hyaluronan & cytokine synthesis in fibrocytes: Potential relevance to thyroid associated ophthalmopathy. J Clin Endocrinol Metab (2020) 106:e20–33. doi: 10.1210/clinem/dgaa684
85. Antonelli A, Ferrari SM, Fallahi P. Slit2 regulation of hyaluronan & cytokine synthesis in fibrocytes in thyroid associated ophthalmopathy. J Clin Endocrinol Metab (2020) 136:dgaa959. doi: 10.1210/clinem/dgaa959
86. Rotondo Dottore G, Torregrossa L, Caturegli P, Ionni I, Sframeli A, Sabini E, et al. Association of T and B cells infiltrating orbital tissues with clinical features of graves orbitopathy. JAMA Ophthalmol (2018) 136:613–9. doi: 10.1001/jamaophthalmol.2018.0806
87. Draman MS, Ludgate M. Thyroid eye disease — an update. Expert Rev Ophthalmol (2016) 11:273–84. doi: 10.1080/17469899.2016.1202113
88. Boskovic O, Medenica S, Radojevic N, Zarkovic M. Etanercept in the treatment of Graves’ ophthalmopathy with primary hypothyroidism and rheumatoid arthritis. Cent Eur J Immunol (2019) 44:463–5. doi: 10.5114/ceji.2019.92803
89. Paridaens D, van den Bosch WA, van der Loos TL, Krenning EP, van Hagen PM. The effect of etanercept on Graves’ ophthalmopathy: a pilot study. Eye (Lond) (2005) 19:1286–9. doi: 10.1038/sj.eye.6701768
90. Kumari R, Chandra Saha B. Advances in the management of thyroid eye diseases: An overview. Int Ophthalmol (2018) 38:2247–55. doi: 10.1007/s10792-017-0694-0
91. Strianese D. Update on Graves disease: advances in treatment of mild, moderate and severe thyroid eye disease. Curr Opin Ophthalmol (2017) 28:505–13. doi: 10.1097/ICU.0000000000000402
92. Strianese D. Efficacy and Safety of Immunosuppressive Agents for Thyroid Eye Disease. Ophthalmic Plast Reconstr Surg (2018) 34(4S Suppl 1):S56–9. doi: 10.1097/IOP.0000000000001131
93. Komorowski J, Jankiewicz-Wika J, Siejka A, Lawnicka H, Kłysik A, Goś R, et al. Monoclonal anti-TNF-alpha antibody (infliximab) in the treatment of patient with thyroid associated ophthalmopathy. Klin Oczna (2007) 109:457–60.
94. Ayabe R, Rootman DB, Hwang CJ, Ben-Artzi A, Goldberg R. Adalimumab as steroid-sparing treatment of inflammatory-stage thyroid eye disease. Ophthalmic Plast Reconstr Surg (2014) 30:415–9. doi: 10.1097/IOP.0000000000000211
95. Pérez-Moreiras JV, Alvarez-López A, Gómez EC. Treatment of active corticosteroid-resistant graves’ orbitopathy. Ophthalmic Plast Reconstr Surg (2014) 30:162–7. doi: 10.1097/IOP.0000000000000037
96. de-Pablo-Gómez-de-Liaño L, Fernández-Vigo JI, Troyano-Rivas J, Niño-Rueda C, Romo-López Á, Gómez-de-Liaño R. Response to tocilizumab treatment in Graves’ ophthalmopathy by measuring rectus muscle thickness and chemosis using optical coherence tomography. Arch Soc Esp Oftalmol (2018) 93:386–91. doi: 10.1016/j.oftal.2018.04.011
Keywords: corticosteroids, cytokines, Graves’ ophthalmopathy, rituximab, teprotumumab, tocilizumab
Citation: Fallahi P, Ferrari SM, Elia G, Ragusa F, Paparo SR, Patrizio A, Camastra S, Miccoli M, Cavallini G, Benvenga S and Antonelli A (2021) Cytokines as Targets of Novel Therapies for Graves’ Ophthalmopathy. Front. Endocrinol. 12:654473. doi: 10.3389/fendo.2021.654473
Received: 16 January 2021; Accepted: 24 March 2021;
Published: 16 April 2021.
Edited by:
Marian Elizabeth Ludgate, Cardiff University, United KingdomReviewed by:
Miloš Žarković, University of Belgrade, SerbiaMohd Shazli Draman, KPJ Damansara Specialist Hospital, Malaysia
Copyright © 2021 Fallahi, Ferrari, Elia, Ragusa, Paparo, Patrizio, Camastra, Miccoli, Cavallini, Benvenga and Antonelli. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Alessandro Antonelli, alessandro.antonelli@med.unipi.it